English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA review by the American College of Physicians (ACP) of performance measures designed to evaluate quality of care for those suffering from major depressive disorder (MDD) found only one of eight measures relevant to internal medicine physicians to be valid. The paper is published in Annals of Internal Medicine.
Tag: Major depressive disorder (MDD)
American College of Physicians recommends cognitive behavioral therapy or second-generation antidepressants for adults with major depressive disorder
The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder (MDD). In the updated clinical guideline, ACP recommends the use of either cognitive behavioral therapy (CBT) or second-generation antidepressants (SGAs) as initial treatment in adults with moderate to severe MDD, and suggests the combination of both, as an alternate initial treatment option. The guideline and supporting evidence reviews are published in Annals of Internal Medicine.
Engineering Research Provides Non-Invasive Solutions for Diagnosing and Treating Neurological and Psychiatric Conditions
Could artificial intelligence help solve the mental health crisis? What if an algorithm allowed neurologists to know the area affected by a brain seizure? These are just a few of the questions that Maryam Ravan, Ph.D., assistant professor of electrical and…
Magnus Medical Launches with Breakthrough Device Designation for Rapid, Individualized Treatment of Major Depression and $25M in Series A Financing
Magnus Medical, Inc., a medical device company, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its individualized, rapid-acting, non-invasive neurostimulation technology designed to treat major depressive disorder (MDD) in people who have not improved sufficiently from antidepressant medication or other treatments.